InCeRT spacer implants are drug-releasing implants for local chemo- and chemoradiation theapy for a variety of cancers. We are currently pursuing manufacturing and approval of IND application for a Phase I clinical trial.
NanoTalazoparib is a novel nanoparticle formulation of the PARP inhibitor Talazoparib that is being tested in pre-clinical studies in ovarian, breast, and lung cancer and Ewings sarcoma animal models, and is ready for scale-up pharmaceutical manufacturing for IND enabling studies.
Dr. Srinivas Sridhar, Founder, TheraNano LLC., University Distinguished Professor of Physics, Bioengineering and Chemical Engineering at Northeastern University and Lecturer on Radiation Oncology, Harvard Medical School. He is the inventor and developer of the QUTE-CE MRA, InCeRT and InCeT implant technologies. For over 30 years he has been studying and developing new drug delivery and imaging technologies for clinical translation. His research has led to more than 200 peer-reviewed journal publications, several patents issues and applications pending, and more than 2015 presentations at international and national conferences and research institutions. He is an expert in nanomedicine, MRI Physics, and neurotechnology. Sridhar’s work is focused on translating his research discoveries into commercial and clinical products with a focus on improving human health. In addition to his research and entrepreneurial activities, he has held numerous research and administrative leadership positions, supervising small groups as well as large multi-M$ organizations.
Theranano employs several domain experts for research, regulatory affairs, scale-up manufacturing, compliance and business management and development.
The company’s location in Boston near the Longwood medical area provides access to an extraordinary pool of experts in medical research. TheraNano has a special asset in a roster of outstanding clinicians and medical researchers who collaborate and advise the company.